Medical Information Only. Consult your healthcare provider before considering clinical trial enrollment.
Metastatic Cervical Cancer: early-phase trial registry
2 of 5 indexed Metastatic Cervical Cancer trials are currently recruiting, with more weight in Phase 1-2.
Corpus placement: #3,391 of 28,707 conditions by registered trial count.
5 US clinical trials · 2 currently recruiting · #3,391 of 28,707 conditions by registered trial count
Metastatic Cervical Cancer: 5 US clinical trials tracked, 2 recruiting.
Metastatic Cervical Cancer is the subject of 5 registered US clinical trials on ClinicalTrials.gov, 2 of them currently open to new participants. 0 are in Phase 3-4 (later-stage) and 4 in Phase 1-2 (earlier-stage). The most active sponsor is Meghan Shea, running 1 of these trials.
Enrollment posture brief
Registry condition metastatic-cervical-cancer
OPEN 2 | RECR 40% | LATE 0 | EARLY 4 | RANK #3391 | SPON 1
Volume-matched condition peers
Nearest open-share peer: Achondroplasia (40% recruiting · 10 trials)
Metastatic Cervical Cancer lists 2 open slots (40% of 5 indexed trials). Peers are matched on registered volume, not therapeutic-area browse lists. How peer matching works →
Key findings
What ClinicalTrials.gov does not surface for Metastatic Cervical Cancer on its own pages , computed from the registry mirror as of 2026-08-08. Each line carries its own denominator so it can be quoted as it stands.
-
Metastatic Cervical Cancer is recruiting below its size-band peers.
2 of 5 indexed trials (40%) are open to enrollment, against a 46.5% average across 27,806 conditions with fewer than 20 trials. The peer set uses the same ClinicalTrials.gov-derived counts as this page.
-
One sponsor concentrates Metastatic Cervical Cancer research.
Meghan Shea accounts for 1 of 5 trials (20%). 5 distinct sponsors appear on at least one study for this condition label.
-
Most Metastatic Cervical Cancer trials plan to enrol fewer than 100 people.
Median target enrolment is 66 among the 5 trials that report a genuine target (sentinel values excluded). 3 of those (60%) plan for fewer than 100 participants.
-
Metastatic Cervical Cancer research is mostly interventional.
5 interventional and 0 observational studies make up this index (100% interventional). Study type is sponsor-reported on ClinicalTrials.gov.
Open and recent trials
5 total, page 1 of 1
PRGN-2009 in Combination With Pembrolizumab Versus Pembrolizumab in Patients With Recurrent or Metastatic Cervical Cancer
Precigen
NCT06157151
Pembrolizumab and Lenvatinib in Advanced Cervical Cancer
Georgetown University
NCT04865887
Self-Hypnosis for the Enhanced Recovery After Surgery in Patients With Gynecologic Cancer
M.D. Anderson Cancer Center
NCT04266886
Dostarlimab and Cobolimab in Advanced Cervical Cancer
Meghan Shea
NCT06238635
Pazopanib Plus Lapatinib Compared to Lapatinib Alone and Pazopanib Alone In Subjects With Metastatic Cervical Cancer
GlaxoSmithKline
NCT00430781
Phase Distribution
| Phase | Trial count |
|---|---|
| Phase 2 | 4 |
Top Sponsors
Named interventions
Most-linked intervention names on Metastatic Cervical Cancer records (sponsor-reported on ClinicalTrials.gov). Counts are trial links, not unique products.
US sites by state
Facility locations filed on Metastatic Cervical Cancer trials. A trial with sites in several states counts in each.
Source: ClinicalTrials.gov, National Library of Medicine. Data is informational only.
Related
What to do with this Metastatic Cervical Cancer page
5 registered trials, 2 currently recruiting, is a starting point for a conversation, not a diagnosis or a recommendation.
- 2 Metastatic Cervical Cancer trials are currently recruiting, check eligibility criteria before contacting a site. Browse recruiting trials
- Meghan Shea sponsors the most Metastatic Cervical Cancer trials on record, review their full trial history before evaluating a specific study. See Meghan Shea's trials
- Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide
Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This Metastatic Cervical Cancer condition card totals 5 registered trials; most-linked intervention lapatinib (GW572016); top US site state Texas. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.